We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CASBF market cap is 278.61M. The company's latest EPS is CNY -6.8548 and P/E is -0.31.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 1.13M | 0 | 18.54M | 4.3B | 1.03B |
| Operating Income | -151.22M | -204.21M | -440.32M | 1.8B | -1.45B |
| Net Income | -138.28M | -156.77M | -396.64M | 1.91B | -909.43M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 795.88M | 1.78B | 6.75B | 11.87B | 11.47B |
| Total Liabilities | 293.56M | 313.98M | 677.22M | 3.33B | 4.22B |
| Total Equity | 502.32M | 1.47B | 6.07B | 8.55B | 7.25B |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -123.64M | -170.19M | -469.39M | 2.01B | -1.89B |
| Investing | 117.63M | -797.77M | -182.71M | -2.53B | -1.19B |
| Financing | 45.06M | 1.09B | 4.92B | 1.56B | 854.6M |
| Market Cap | 278.61M |
| Price to Earnings Ratio | -0.31 |
| Price to Sales Ratio | 0.27 |
| Price to Cash Ratio | 0.08 |
| Price to Book Ratio | 0.04 |
| Dividend Yield | - |
| Shares Outstanding | 132.67M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -51.99% |
| 52 Week High | 4.3745 |
| 52 Week Low | 1.86 |
| Spread (Intraday) | 0.26 (8.97%) |
| Company Name | Cansino Biologics Inc (PK) |
| Address |
401-420, 4th floor tianjin |
| Website | https://www.cansinotech.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
